H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

The 2009 A (H1N1) influenza virus pandemic: A review

(2010) Marc P. Girard et al.   VACCINE

Current status and progress of prepandemic and pandemic influenza vaccine development

(2009) Isabel Leroux-Roels et al.   Expert Review of Vaccines

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

(2009) Daniel Wai-Sing Chu et al.   VACCINE

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults

(2009) Tino F. Schwarz et al.   VACCINE

Type I interferon as a stimulus for cross-priming

(2008) A LEBON et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Standardization and optimization of multiparameter intracellular cytokine staining

(2008) Laurel Nomura et al.   CYTOMETRY PART A

Vaccine Adjuvants Alter TCR-Based Selection Thresholds

(2008) Laurent Malherbe et al.   IMMUNITY

Generation of T Follicular Helper Cells Is Mediated by Interleukin-21 but Independent of T Helper 1, 2, or 17 Cell Lineages

(2008) Roza I. Nurieva et al.   IMMUNITY

An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults

(2008) Karin Levie et al.   JOURNAL OF INFECTIOUS DISEASES

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

(2008) Benoît Baras et al.   PLoS One

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE